Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary

Dy, GK; Govindan, R; Velcheti, V; Falchook, GS; Italiano, A; Wolf, J; Sacher, AG; Takahashi, T; Ramalingam, SS; Dooms, C; Kim, DW; Addeo, A; Desai, J; Schuler, M; Tomasini, P; Hong, DS; Lito, P; Tran, Q; Jones, S; Anderson, A; Hindoyan, A; Snyder, W; Skoulidis, F; Li, BT

Author(s): Dy, GK; Govindan, R; Velcheti, V; Falchook, GS; Italiano, A; Wolf, J; Sacher, AG; Takahashi, T; Ramalingam, SS; Dooms, C; Kim, DW; Addeo, A; Desai, J; Schuler, M; Tomasini, P; Hong, DS; Lito, P; Tran, Q; Jones, S; Anderson, A; Hindoyan, A; Snyder, W; Skoulidis, F; Li, BT;
Details: Publication Year 2024-01,Volume 20,Issue #3,Page 113-120
Journal Title: Future Oncology
Publication Type: Review
Abstract: WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer. CodeBreaK 100 specifically looked at patients with a particular change(mutation) in the KRAS gene resulting in the mutated protein called KRAS G12C. The KRAS G12C mutation can lead to development and growth of lung cancer. Patients received a treatment called sotorasib, which has accelerated approval or full approval in over 50 countries for patients with non-small-cell lung cancer with the KRAS G12C mutation. The CodeBreaK 100 study looked at whether sotorasib is a safe and effective treatment for advanced non-small-cell lung cancer. Sotorasib is designed to specifically target and lock the mutated KRAS protein in the inactive state to treat non-small-cell lung cancer. WHAT WERE THE RESULTS? In total, 174 adults were treated with sotorasib. Treatment-related side effects were seen in 70% of patients and were severe in 21% of patients. The most common side effects included diarrhea, increased liver enzymes, nausea and tiredness. 70 (41%) patients responded to sotorasib and 144 (84%) patients had tumors that either remained stable or shrunk in size. 29 (41%) patients who responded to sotorasib responded for over 12 months. After 2 years, 9 patients with a response remained on sotorasib; there were no notable increases in tumor size or development of new tumors over this time. There were 5patients who received sotorasib for more than 2 years and continued to respond. Long-term benefit was seen for some patients. Patients also benefitted from treatment when the tumor expressed different amounts of a protein called PD-L1.In total, 33% of patients were still alive after 2 years. WHAT DO THE RESULTS MEAN? Results show the long-term benefit of sotorasib therapy for people with advanced KRAS G12C-mutated non-small-cell lung cancer. Clinical Trial Registration: NCT03600883 (CodeBreaK 100) (ClinicalTrials.gov).
Publisher: Future Medicine
Keywords: Adult; Humans; *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics; *Lung Neoplasms/drug therapy/genetics; Proto-Oncogene Proteins p21(ras)/genetics; Language; Mutation; *Piperazines; *Pyridines; *Pyrimidines; Clinical trials; Lung; Metastasis
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.2217/fon-2023-0560
Open Access at Publisher's Site: https://doi.org/10.2217/fon-2023-0560
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-03-05 04:47:27

Last Modified: 2024-03-05 04:47:58